Hasil Pencarian  ::  Simpan CSV :: Kembali

Abstrak :
BAKTI bekerja sama dengan PT. XYZ sebagai penyedia kapasitas dalam Proyek USO (Universal Service Obligation) menggunakan teknologi High Throughput Satellite dan memiliki 12 (dua belas) spot-beam Ku-band untuk mencakup semua wilayah Indonesia. PT. XYZ memiliki total kapasitas 1.314 MHz dalam arah forward dan 625.2 MHz dalam arah return untuk 12 (dua belas) spot-beam. Pada Proyek USO Penyediaan Kapasitas Satelit, ada dua jenis layanan yang disediakan, yaitu layanan ground segment Akses Internet dan Backhaul BTS dengan bandwidth aggregate 8 Mbps. Dalam memenuhi kebutuhan layanan ground segment Akses Internet dan Backhaul BTS, out-route pada setiap spot-beam dibagi menjadi 2 (dua), untuk layanan Akses Internet  dan Backhaul BTS dengan pembagian out-route yaitu sebesar 50% dari total kapasitas out-route untuk out-route satu (Akses Internet) dan 50% dari total kapasitas out-route ke out-route dua (Backhaul BTS). Namun, pada setiap beam jumlah remote Akses Internet dan Backhaul BTS tidak sama pada setiap beam sehingga hal ini menyebabkan tidak seimbangnya pembagian kapasitas out-route. Ada beberapa beam yang harus di-setting kembali untuk pembagian out-route satu dan out-route duanya. Dari latar belakang permasalahan tersebut, maka diperlukan dimensioning kapasitas out-route dan in-route yang tepat berdasarkan alokasi site ground segment pada setiap beam dan sesuai dengan persyaratan yang diberikan oleh BAKTI. Hasil dari analisa pada penelitian ini dapat disimpulkan bahwa PT. XYZ harus segera melakukan reshaping out-route sesuai dengan hasil perhitungan pada analisis. Proses reshaping out-route dapat dilakukan dengan mengikuti langkah-langkah yang sudah dijabarkan pada diagram alur proses reshaping out-route. Setelah melakukan reshaping out-route sesuai dengan hasil analisis perhitungan di atas, maka ground segment Backhaul BTS akan mendapatkan alokasi bandwidth CIR download yang telah dijamin oleh PT. XYZ ke BAKTI yaitu sebesar 6 Mbps.

---

BAKTI in collaboration with PT. XYZ as a capacity provider in the USO Project (Universal Service Obligation) uses High Throughput Satellite technology and has 12 (twelve) Ku-band spots to cover all regions of Indonesia. PT. XYZ has a total capacity of 1,314 MHz in the forward direction and 625.2 MHz in the return direction for 12 (twelve) spot-beams. In the USO Project for Provision of Satellite Capacity, there are two types of services provided, namely ground segment Internet access services and BTS Backhaul with 8 Mbps aggregate bandwidth. In meeting the needs of ground access services for Internet Access and Backhaul BTS, out-route at each spot-beam is divided into 2 (two), for Internet Access and Backhaul BTS services by out-route sharing, which is 50% of the total out-route capacity for out-route one (Internet access) and 50% of total out-route capacity to out-route two (Backhaul BTS). However, in each beam, the number of remote Internet Access and Backhaul BTS is not the same so this causes an uneven distribution of out-route capacity. Several beams must be set back to divide out-route one and out-route both. From the background of these problems, it is necessary to dimensioning the appropriate out-route and in-route capacity based on the allocation of the site ground segment on each beam and by the requirements given by BAKTI. The results of the analysis in this study can be concluded that PT. XYZ must immediately be reshaping out-route according to the calculation results in the analysis. The out-route reshaping process can be done by following the steps outlined in the out-route reshaping process flowchart. After reshaping the out-route by the results of the calculation analysis above, the Backhaul BTS ground segment will get a downloadable CIR bandwidth allocation that has been guaranteed by PT. XYZ to BAKTI which is 6 Mbps.

Abstrak :
Penyakit kardiovaskular adalah salah satu penyebab kematian yang banyak di dunia saat ini. Salah satu penyebab penyakit kardiovaskular adalah trombosis arterial yang bisa disebabkan oleh agregrasi platelet yang menutup arteri. Salah satu faktor penting dalam agregrasi platelet adalah aktivasi platelet oleh ADP dengan reseptor P2Y 12. Penelitian ini dilakukan untuk mencari kandidat inhibitor ADP P2Y 12 yang berasal dari tanaman herbal Indonesia menggunakan AutoDock dan AutoDock Vina. 96 senyawa yang terbukti memiliki aktivitas inhibisi terhadap ADP P2Y12 digunakan sebagai kontrol positif dan digunakan untuk membuat pengecoh pada DUD-E dengan mengunggah kontrol positif ke laman DUD-E. Penapisan yang dilakukan mendapatkan satu senyawa aktif yang berpotensi sebagai inhibitor P2Y 12 yaitu Roxburghine B yang berikatan pada residu asam amino yang penting Lys280 dan Arg256. ...... Cardiovascular desease is one of the leading causes of death in the world. One of the causes of cardiovascular disease is artherial thrombosis that can be caused by platelet agregration that is covered in arteries. One of important factor in platelet agregration is platelet activation by ADP receptors, P2Y 12. This research was conducted to find candidate inhibitor of P2Y 12 from Indonesian herbal plants database using AutoDock and AutoDock Vina. Ninety six compounds known for their inhibitory activity against P2Y 12 were used as actives and as reference for generating decoys on DUD E by upload positive control to DUD E website. The virtual screening yields one potential P2Y 12 inhibitor. Roxburghine B binds to important amino acid residues of Lys280 and Arg256.

Abstrak :
Born out of a project of the IUPAC's committee on Medicinal Chemistry and Drug Development, this reference addresses past and current strategies for successful drug analog development, extending the previously published volume by nine new analog classes and eight case studies. Like its precursor, this volume also contains a general section discussing universally applicable strategies for analog discovery and development. Spanning a wide range of therapeutic fields and chemical classes, the two volumes together constitute the first systematic approach to drug analog development.

Abstrak :
New strategies and techniques for today's fast-paced discovery process. Today, the pressure is on for high-throughput approaches to accelerate the generation, identification, and optimization of molecules with desirable drug properties. As traditional methods of analysis become antiquated, new analytical strategies and techniques are necessary to meet sample throughput requirements and manpower constraints. Among them, mass spectrometry has grown to be a front-line tool throughout drug discovery. Integrated Strategies for Drug Discovery Using Mass Spectrometry provides a thorough review of current analytical approaches, industry practices, and strategies in drug discovery. The topics represent current industry benchmarks in specific drug discovery activities that deal with proteomics, biomarker discovery, metabonomic approaches for toxicity screening, lead identification, compound libraries, quantitative bioanalytical support, biotransformation, reactive metabolite characterization, lead optimization, pharmaceutical property profiling, sample preparation strategies, and automation. THIS BOOK: Clearly explains how drug discovery and mass spectrometry are interconnected Discusses the uses and limitations of various types of mass spectrometry in various aspects of drug discovery Prominently features analytical applications that require trace-mixture analysis Provides industry applications and real-world examples Shares historical background information on various techniques to aid in the understanding of how and why new methods are now being employed to analyze samples.

Abstrak :
This resource provides an integrated and comprehensive overview of modern approaches to drug lead discovery. Each chapter in this book reviews the theoretical background and application of a key technology in drug discovery, complemented by relevant case studies. The coverage includes the key approaches for drug design and discovery, high-throughput screening, fragment screening, multi-target drugs, de novo design, ADMET, natural products. This cutting-edge reference helps medicinal chemists in biotech, pharmaceutical, and other research contexts consider all possible avenues in starting their drug research programs.

Abstrak :
The first authoritative overview of past and current strategies for successful drug development by analog generation, this unique resource spans all important drug classes and all major therapeutic fields, including histamine antagonists, ACE inhibitors, beta blockers, opioids, quinolone antibiotics, steroids and anticancer platinum compounds. Of the 19 analog classes presented in detail, 9 are described by the scientists who discoverd them. The book includes a table of the most successful drug analogs as based on the IMS ranking and compares them in terms of chemical structure, mode of action and patentability.

Abstrak :
Drug discovery is all about finding small molecules that interact in a desired way with larger molecules, namely proteins and other macromolecules in the human body. If the three-dimensional structures of both the small and large molecule are known, their interaction can be tested by computer simulation with a reasonable degree of accuracy. Alternatively, if active ligands are already available, molecular similarity searches can be used to find new molecules. This virtual screening can even be applied to compounds that have yet to be synthesized, as opposed to "real" screening that requires cost- and labor-intensive laboratory testing with previously synthesized drug compounds. Unique in its focus on the end user, this is a real "how to" book that does not presuppose prior experience in virtual screening or a background in computational chemistry. It is both a desktop reference and practical guide to virtual screening applications in drug discovery, offering a comprehensive and up-to-date overview. Clearly divided into four major sections, the first provides a detailed description of the methods required for and applied in virtual screening, while the second discusses the most important challenges in order to improve the impact and success of this technique. The third and fourth, practical parts contain practical guidelines and several case studies covering the most important scenarios for new drug discovery, accompanied by general guidelines for the entire workflow of virtual screening studies. Throughout the text, medicinal chemists from academia, as well as from large and small pharmaceutical companies report on their experience and pass on priceless practical advice on how to make best use of these powerful methods.

Abstrak :
Backed by leading authorities, this is a professional guide to successful compound screening in pharmaceutical research and chemical biology, including the chemoinformatic tools needed for correct data evaluation. The authors discuss such factors as chemical genetics, binding, cell-based and biochemical assays, the efficient use of compound libraries and data mining using cell-based assay results.